Drug Trial Radar · NCT02130063
IDA-01 A Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose
Last checked: Nov 20, 2026Latest source record: Sep 27, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
511
Actual
Start
May 2014
Primary completion
Aug 2015
Study completion Aug 2015
Sponsor
- Lead sponsor
- Pharmacosmos A/SIndustry
- Sponsor type
- Industry
- Collaborators
- BioStata; ClinStar, LLC; Laboratory Corporation of America
- First posted
- May 2, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the trial is to evaluate and compare the effect of iron isomaltoside 1000 to iron sucrose in its ability to increase haemoglobin (Hb) in subjects with IDA when oral iron preparations are ineffective or cannot be used or where there is a clinical need to deliver iron rapidly.
Conditions
- Iron Deficiency Anaemia
Interventions
iron isomaltoside 1000 (Monofer®)Drug
iron sucrose (Venofer®)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects With an Haemoglobin (Hb) Increase of ≥ 2 g/dL From Baseline at Any Time From Week 1 to Week 5Time frame: From baseline to week 5
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site not named
Wilmington, Delaware
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.